Cytomegalovirus immunoglobulin therapy for CMV retinitis post hematopoietic stem cell transplantation.

Authors :: Chiu TY
Huang MY
Wu HJ
Source :: European journal of ophthalmology [Eur J Ophthalmol] 2023 Jul; Vol. 33 (4), pp. NP101-NP104. Date of Electronic Publication: 2022 Jul 11.
Publication Year :: 2023
Abstract: Purpose: To report a case of cytomegalovirus (CMV) retinitis complicated with ganciclovir-related myelosuppression, which was successfully managed with intravenous (IV) ganciclovir and CMV immunoglobulin (CMVIG) therapy.<br />Methods: Observational case report.<br />Results: A 51-year-old male with follicular type non-Hodgkin lymphoma post hematopoietic stem cell transplantation (HSCT) developed vision-threatening retinitis. polymerase chain reaction (PCR) of the aqueous humour showed positive for CMV. Despite myelosuppression occurred during IV ganciclovir therapy, the retinitis resolved and intraocular CMV viral load significantly improved after CMVIG therapy.<br />Conclusion: Combined IV ganciclovir treatment and CMVIG therapy can significantly improve visual outcome and reduce intraocular CMV viral load in vision-threatening CMV retinitis.

Subjects :: Humans
Male
Middle Aged
Antiviral Agents therapeutic use
Cytomegalovirus genetics
Ganciclovir adverse effects
Ganciclovir therapeutic use
Immunization, Passive
Cytomegalovirus Retinitis diagnosis
Cytomegalovirus Retinitis drug therapy
Cytomegalovirus Retinitis etiology
Hematopoietic Stem Cell Transplantation adverse effects

Full Text Access

Tools